

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>KAPP STEVEN</u> (Last) (First) (Middle) <u>C/O CORCEPT THERAPEUTICS INCORPORATED</u> <u>275 MIDDLEFIELD ROAD</u> (Street) <u>MENLO PARK, CA CA 94025</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>04/14/2004</u>	3. Issuer Name and Ticker or Trading Symbol <u>CORCEPT THERAPEUTICS INC [CORT]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
No securities owned	0 ⁽¹⁾⁽²⁾	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				

Explanation of Responses:

1. The Reporting Person is a limited partner of Maverick Capital, Ltd., the investment adviser to (i) Maverick Fund, L.D.C. ("LDC"), which will hold 1,320,444 shares of common stock of Corcept Therapeutics Incorporated (the "Issuer") (to be acquired as a result of the conversion of Series C preferred shares in connection with the Issuer's initial public offering), (ii) Maverick Fund II, Ltd. ("Fund II"), which will hold 194,999 shares of common stock of the Issuer (to be acquired as a result of the conversion of Series C preferred shares in connection with the Issuer's initial public offering) and (iii) Maverick Fund USA, Ltd. ("Fund USA"), which will hold 607,398 shares of common stock of the Issuer (to be acquired as a result of the conversion of Series C preferred shares in connection with the Issuer's initial public offering).

2. Maverick Capital, Ltd. receives an investment advisory fee for its services to LDC, Fund II and Fund USA; the Reporting Person has an interest in such investment advisory fee. The Reporting Person is also a limited partner of Maverick Capital Advisors, L.P., the general partner of Fund USA. The Reporting Person disclaims beneficial ownership of the equity securities of the Issuer held by LDC, Fund II and Fund USA, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such equity securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purposes.

Remarks:

Exhibit List Exhibit 24 -- Power of Attorney

/s/ Fred Kurland, CFO of
Corcept Therapeutics 04/14/2004
Incorporated attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Exhibit 24

POWER OF ATTORNEY FOR SECTION 16 REPORTING

The undersigned hereby appoints Joseph K. Belanoff, in his capacity as Chief Executive Officer of Corcept Therapeutics Incorporated (the "Company"), Andrew Galligan, in his capacity as Chief Financial Officer of the Company, and either of them with full power of substitution or their respective successors in any such offices, as the attorney-in-fact of the undersigned to execute and file with the Securities and Exchange Commission ("SEC") and any other authority required by the rules and regulations of the SEC or any market or exchange on which shares of the Company are traded and to submit to the Company, in the place and stead of the undersigned, SEC Forms 3, 4 and 5 and any successor reporting forms required by the SEC in connection with purchases and sales of securities of the Company and any other transactions in securities of the Company reportable on any such form. This Power of Attorney shall be effective until revoked by a written instrument executed by the undersigned and delivered to the Company at its headquarters to the attention of the Chief Financial Officer.

Dated: February 5, 2002

/s/ Steve Kapp

Name: Steve Kapp